{"id":"vehicle-ophthalmic-solution-qid","safety":{"commonSideEffects":[{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Conjunctival hyperemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"It serves as a control in clinical studies to help differentiate the effects of the active drug from the placebo. The solution is designed to mimic the physical properties of potential active treatments without containing any active pharmaceutical ingredients.","oneSentence":"Vehicle Ophthalmic Solution QID is a carrier solution used in clinical trials to deliver active drugs to the eye, without having a direct therapeutic effect itself.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:40:26.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Used as a control in clinical trials for ophthalmic conditions"}]},"trialDetails":[{"nctId":"NCT06978244","phase":"PHASE1","title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bausch & Lomb Incorporated","startDate":"2025-07-29","conditions":"Ocular Pain","enrollment":24},{"nctId":"NCT05411367","phase":"PHASE3","title":"A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye","status":"COMPLETED","sponsor":"Seikagaku Corporation","startDate":"2022-07-28","conditions":"Dry Eye Disease","enrollment":232},{"nctId":"NCT04735393","phase":"PHASE3","title":"A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2021-01-26","conditions":"Dry Eye Disease","enrollment":757},{"nctId":"NCT06424444","phase":"PHASE3","title":"A Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2024-04-29","conditions":"Dry Eye Disease","enrollment":421},{"nctId":"NCT07068958","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of RCI001 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"ORA, Inc.","startDate":"2025-08-01","conditions":"Dry Eye Disease (DED)","enrollment":200},{"nctId":"NCT06352541","phase":"PHASE1","title":"Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.","status":"NOT_YET_RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-09-30","conditions":"Healthy","enrollment":28},{"nctId":"NCT04276558","phase":"PHASE2","title":"REC 0/0559 Eye Drops for Treatment of Moderate and Severe Neurotrophic Keratitis in Adult Patients","status":"COMPLETED","sponsor":"RECORDATI GROUP","startDate":"2020-10-13","conditions":"Neurotrophic Keratitis","enrollment":108},{"nctId":"NCT03660878","phase":"PHASE1, PHASE2","title":"A Methodology Development Environmental Clinical Trial of Reproxalap in Subjects With Seasonal Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2018-09-08","conditions":"Allergic Conjunctivitis","enrollment":52},{"nctId":"NCT04674358","phase":"PHASE2, PHASE3","title":"The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2020-11-21","conditions":"Dry Eye, Dry Eye Syndromes","enrollment":329},{"nctId":"NCT03916042","phase":"PHASE2","title":"A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Clinical Trial of Reproxalap to Assess the Safety and Efficacy in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2019-04-23","conditions":"Dry Eye","enrollment":206},{"nctId":"NCT04097730","phase":"PHASE3","title":"Steroids and Cross-linking for Ulcer Treatment","status":"COMPLETED","sponsor":"Thomas M. Lietman","startDate":"2020-09-24","conditions":"Keratitis Bacterial","enrollment":280},{"nctId":"NCT03879863","phase":"PHASE3","title":"The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2019-04-16","conditions":"Dry Eye","enrollment":422},{"nctId":"NCT04250207","phase":"PHASE2","title":"Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2020-06-23","conditions":"Fuchs' Endothelial Corneal Dystrophy","enrollment":65},{"nctId":"NCT04909450","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects","status":"COMPLETED","sponsor":"Claris Biotherapeutics, Inc.","startDate":"2021-08-24","conditions":"Neurotrophic Keratitis","enrollment":131},{"nctId":"NCT05409235","phase":"PHASE2","title":"Nesvategrast (OTT166) in Diabetic Retinopathy (DR)","status":"COMPLETED","sponsor":"OcuTerra Therapeutics, Inc.","startDate":"2022-07-29","conditions":"Diabetic Retinopathy","enrollment":225},{"nctId":"NCT03693183","phase":"PHASE2","title":"Efficacy Study of Ketorolac and HPMC to Treat Dry Eye","status":"WITHDRAWN","sponsor":"ORA, Inc.","startDate":"2009-03","conditions":"Dry Eye","enrollment":""},{"nctId":"NCT05995392","phase":"EARLY_PHASE1","title":"The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease","status":"UNKNOWN","sponsor":"Richard W Yee, MD","startDate":"2023-08","conditions":"Dry Eye Disease","enrollment":30},{"nctId":"NCT03937882","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3","status":"COMPLETED","sponsor":"ReGenTree, LLC","startDate":"2019-05-24","conditions":"Dry Eye Syndromes, Dry Eye","enrollment":700},{"nctId":"NCT02974907","phase":"PHASE3","title":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2","status":"COMPLETED","sponsor":"ReGenTree, LLC","startDate":"2016-11","conditions":"Dry Eye Syndrome","enrollment":601},{"nctId":"NCT04222725","phase":"PHASE1, PHASE2","title":"A Study of TRS01 in Participants With Post-surgical Ocular Inflammation","status":"COMPLETED","sponsor":"Tarsier Pharma","startDate":"2020-02-01","conditions":"Post Surgical Ocular Inflammation","enrollment":37},{"nctId":"NCT03131167","phase":"PHASE1","title":"Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Shire","startDate":"2017-05-10","conditions":"Primary Open-angle Glaucoma (POAG), Ocular Hypertension","enrollment":63},{"nctId":"NCT02929823","phase":"PHASE2","title":"Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders","status":"COMPLETED","sponsor":"Senju Pharmaceutical Co., Ltd.","startDate":"2016-09","conditions":"Corneal Epithelial Disorders","enrollment":130},{"nctId":"NCT02104388","phase":"PHASE2","title":"Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders","status":"COMPLETED","sponsor":"Senju Pharmaceutical Co., Ltd.","startDate":"2014-04-08","conditions":"Corneal Epithelial Disorders","enrollment":69},{"nctId":"NCT02218489","phase":"PHASE2","title":"Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease","status":"COMPLETED","sponsor":"Kala Pharmaceuticals, Inc.","startDate":"2014-07","conditions":"Blepharitis","enrollment":206},{"nctId":"NCT01797822","phase":"PHASE4","title":"Effects of Dry Eye Treatments on the Ocular Surface","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2013-02","conditions":"Keratoconjunctivitis Sicca, Dry Eye Syndrome","enrollment":20},{"nctId":"NCT02193490","phase":"PHASE1, PHASE2","title":"DNase Treatment for Dry Eyes","status":"TERMINATED","sponsor":"University of Illinois at Chicago","startDate":"2014-07","conditions":"Dry Eye","enrollment":47},{"nctId":"NCT01959243","phase":"PHASE3","title":"Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2014-02-22","conditions":"Hyperemia","enrollment":507},{"nctId":"NCT01959230","phase":"PHASE3","title":"Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-11-07","conditions":"Hyperemia","enrollment":60},{"nctId":"NCT02597803","phase":"PHASE2, PHASE3","title":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1","status":"COMPLETED","sponsor":"ReGenTree, LLC","startDate":"2015-09","conditions":"Dry Eye Syndrome","enrollment":317},{"nctId":"NCT02349516","phase":"PHASE2","title":"Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)","status":"WITHDRAWN","sponsor":"Starr Muscle","startDate":"2015-02","conditions":"Diabetic Retinopathy","enrollment":""},{"nctId":"NCT01877694","phase":"PHASE2","title":"Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"NovaBay Pharmaceuticals, Inc.","startDate":"2013-06","conditions":"Bacterial Conjunctivitis","enrollment":217},{"nctId":"NCT00198536","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2005-04","conditions":"Dry Eye Syndromes","enrollment":159},{"nctId":"NCT01687426","phase":"PHASE1","title":"Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Eye Therapies, LLC","startDate":"2012-09","conditions":"Glaucoma and Ocular Hypertension","enrollment":15},{"nctId":"NCT00833495","phase":"PHASE2","title":"Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation","status":"COMPLETED","sponsor":"Fovea Pharmaceuticals SA","startDate":"2009-01","conditions":"Allergic Conjunctivitis","enrollment":155},{"nctId":"NCT00332774","phase":"PHASE3","title":"Nevanac 3-Month Safety Study With QID Dosing","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-02","conditions":"Cataract","enrollment":149},{"nctId":"NCT00485394","phase":"PHASE2","title":"The OMEGA Study: Use of Eye Drops to Treat Geographic Atrophy Associated With Age-Related Macular Degeneration (Dry AMD)","status":"UNKNOWN","sponsor":"Othera Pharmaceuticals","startDate":"2007-06","conditions":"Age-Related Macular Degeneration","enrollment":198}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Vehicle Ophthalmic Solution QID","genericName":"Vehicle Ophthalmic Solution QID","companyName":"Aldeyra Therapeutics, Inc.","companyId":"aldeyra-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vehicle Ophthalmic Solution QID is used as a control in clinical trials for conditions such as Diabetic Retinopathy, Dry Eye, Corneal Epithelial Disorders, Dry Eye Disease, and Blepharitis. The Vehicle Ophthalmic Solution QID is being studied in a Phase 2 clinical trial (NCT05409235) as a control for the ophthalmic solution OTT166.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}